Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
980.2 USD +1.06% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.49% +11.60%
May. 31 EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
May. 31 Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Regeneron Pharmaceuticals, Inc.

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S. DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 MT
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT

Chart Regeneron Pharmaceuticals, Inc.

Chart Regeneron Pharmaceuticals, Inc.
More charts

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
Biotechnology & Medical Research
Calendar
10:00am - American Society of Clinical Oncology Meeting - Abstract No : 2650
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
980.2 USD
Average target price
1,042 USD
Spread / Average Target
+6.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $9.55, vs. Street Est of $10.10